A Single-blind, Placebo Controlled Sleep Laboratory Study of the Acute Effects of Aplindore in Restless Legs Syndrome.

Trial Profile

A Single-blind, Placebo Controlled Sleep Laboratory Study of the Acute Effects of Aplindore in Restless Legs Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2011

At a glance

  • Drugs Aplindore (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Neurogen Corporation
  • Most Recent Events

    • 10 Aug 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2008 Positive top-line results announced by Neurogen Corporation.
    • 11 Mar 2008 Status changed from initiated to recruiting. Updated from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top